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ABSTRACT 
Background: Multidrug resistance exist within a wide variety of clinically significant 
pathogens and poses a serious and growing global public health threat. This study aimed 
to determine the incidence, patterns, and trends of multidrug resistance of gram-negative 
bacterial isolates in clinical specimens cultured at the Tamale Teaching Hospital 
Laboratory. 
 
Methods: This retrospective study analyzed gram-negative bacteria isolates and 
sensitivity test results of patients who visited the Tamale Teaching Hospital laboratory in 
Ghana, West Africa from 2017 to 2019 
 
Results: A total of 2769 gram-negative bacteria isolates, and their phenotypic AST 
results were analyzed in this study. A total of 1297 gram-negative bacteria were isolated 
from urine samples representing 46.8% of all the isolates followed by isolates from 
sputum samples and wound swabs. Escherichia coli (23.8%) is the highest isolated gram-
negative bacteria in all samples with, predominance from urine samples making up 
33.2%. All gram-negative bacteria isolated from 2017-2019 showed significant multidrug 
resistance between 60% and 95.5%. Klebsiella pneumonia similarly showed increased 
multidrug resistance levels year on year; 2017(84%), 2018(89.5%) and 95.1% in 2019. 
Pseudomonas aeruginosa which showed relatively low multidrug resistance rates 
(65.8%) was, still determined to demonstrate increased resistance from 2017(59.5%) to 
2019(78.7%). Gram-negative bacteria showed the highest susceptibility to antibiotics in 
the aminoglycoside group with amikacin the most effective. Enterobacter spp resistance 
to amikacin was as low as 16.2%, Escherichia coli (11.8%) and Klebsiella pneumoniae 
was determined to be 17.7%. 
 
Conclusion: The study has shown high levels of multidrug-resistant gram-negative 
bacteria commonly isolated as the causative organisms in a range of infections. There is 
high resistance to penicillins, cephalosporins, and fluoroquinolones among major gram-
negative pathogens. Aminoglycosides exhibited the least levels of resistance to isolated 
gram-negative bacteria in the Tamale Teaching Hospital. 
 
Keywords: Gram-negative bacteria, multidrug resistance, Tamale Teaching Hospital 
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1 INTRODUCTION 
1.1 GENERAL INTRODUCTION 
Multidrug resistance (MDR) exist within a wide variety of clinically significant pathogens 
and poses a serious and growing global public health threat.[1]In the 2014 global 
surveillance report on Antimicrobial resistance, the WHO warns of an apocalyptic post-
antimicrobial era, a possible reality in the 21st century. Antimicrobial resistance is a 
sgnificant threat to the prevention and treatment of the wide range of diseases caused 
infectious pathogens. Viruses, bacteria, parasites, and fungi are increasingly becoming 
resistant to the currently available antimicrobial previously effective at treating medical 
conditions due to diseases caused by these microorganisms.Currently , MDR is estimated to 
cause an estimated seven hundred thousand deaths globally.If the situation of the trend of 
resistance is allowed to persist MDR could result in the deaths of over 10 million people per 
year [2]. 
Infections caused by multidrug-resistant bacteria has been particularly challenging in 
developing countries and are mostly accompanied by increased hospital stay and high rates 
of morbidity and mortality [3]. The threat of antimicrobial resistance in low and middle is 
significantly exacerbated due to several practices pervasive in these countries.  A study 
published in 2017 outlined the causes of antimicrobial resistance in developing countries  to 
include; widespread unnecessary and overuse of antimicrobials due to lack of appropriate 
regulations in the sales and administration of antimicrobials, counterfeit and low-quality 
antimicrobials resulting in sub-inhibitory concentration of in vivo and high rate of self-
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medication among others.[4]. Ironically countries in the WHO African region has a 
problem with unavailability of data on AMR[5].All the reasons ascribed to be causes of 
Antimicrobial Resistance in developing countries are prevalent in Ghana and studies into 
AMR have reveal the existence of increasing trends of resistance among several common 
pathogens.[6, 7].  
Over the years the WHO has develop a list of priority of organisms which it deems as 
iminent global health threats to guide research and new antibiotic development.  The 
categorization of these priority pathogens in three levels of severity, includes Pseudomonas 
aeruginosa, Acinetobacter baumannii and Enterobacteriaceae, which all fall within the 
critical priority class of organisms. Other description highlights the threat of these 
pathogens to positive clinical outcomes. Several studies have espoused the clinical 
significance of gram-negative ESKAPE organisms like Klebsiella pneumoniae in hospital 
settings  and Latin America and Asia[8, 9]. ESKAPE gram-negative bacteria are among 
some of the most common organisms implicated in health-care-associated infections. They 
are documented to be rapidly becoming resistant to commonly used broad spectrum 
antibiotics. Not only are these infections prone to negative health outcomes, they are 
contributors to adverse socio-economic impacts by putting significant burden on health care 
systems in low-and-middle-income countries[10]. Due to the high prevalence of multidrug 
resistance among ESKAPE bacteria, as defined by the Infectious Diseases Society of 
America such as Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter spp., these pathogens 
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feature prominently in the global Priority Pathogen List (PPL) of antibiotic-resistant 
bacteria.  
1.2 RESEARCH PURPOSE 
Multidrug resistance is a major public health threat globally and there is an urgent need to 
reverse the current trend of increasing resistance to multiple drugs by organisms. MDR 
issues in low- and middle-income countries will require a coordinated effort from all 
stakeholders. In 2015, the World Health Organization published a global action plan. It 
implores sovereign countries to develop their individual action plans on combating 
antimicrobial resistance using the global action plan as a template.  However, the absence of 
surveillance data on the extent of AMR in low-and-middle-income-countries has hampered 
public health experts to be able to formulate the required measures intended to counter the 
threat of AMR. There is a need to be abreast with the current prevalence and patterns of 
resistance among priority pathogens. This study seeks to provide insight into the prevalence 
and resistance patterns of gram-negative in the northern part of Ghana.  
1.3  SPECIFIC OBJECTIVES 
o To determine the incidence of multidrug resistance of gram-negative bacterial 
isolates in clinical specimen cultured at the Tamale Teaching Hospital Laboratory 
o To determine the profile of antimicrobial resistance among gram-negative 
bacterial isolates in clinical specimen cultured at the Tamale Teaching Hospital 
Laboratory 
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o To determine the trend in Multidrug resistance among gram-negative bacteria 
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2 LITERATURE REVIEW 
2.1 BRIEF HISTORY OF THE DEVELOPMENT OF ANTIMICROBIAL 
AGENTS 
Infectious diseases have accounted for a large proportion of all diseases over the years. By 
the latter part of the 19th century, it was discovered that the causative agent of infectious 
diseases were microorganisms. As a result, a curative agent aimed at microorganism was 
developed. The first antimicrobial agent in the world was salvarsan, a remedy for syphilis 
synthesized by Ehrlich in 1910. In 1935, sulfonamides were developed by Domagk and 
other researchers. These drugs were synthetic compounds and had limitations in terms of 
safety and efficacy. In1928, Fleming discovered penicillin. He found that the growth of 
Staphylococcus aureus was inhibited in a zone surrounding a contaminated blue mold (a 
fungus from the Penicillium genus) in culture dishes, leading to the finding that a 
microorganism would produce substances that could inhibit the growth of other 
microorganisms. The antibiotic was named penicillin, and it came into clinical use in the 
1940s. Penicillin, which is an outstanding agent in terms of safety and efficacy, led in the 
era of antimicrobial chemotherapy.   
   6 
 
Figure 1. Timeline of antibiotic discovery[11] 
2.2 CLASSIFICATION OF ANTIBACTERIAL DRUGS 
Therapeutic antimicrobial agents could be of either natural or synthetic origin. They 
generally work by inhibiting or disrupting vital metabolic processes within the mostly 
bacterial cell, targeting structures or pathways sufficiently different or absent in mammalian 
cells. 
Antibiotics can be grouped according to several criteria: inhibitory effect, the spectrum of 
activity, and molecular target. Some antimicrobial compounds are bactericidal at clinically 
used concentrations and capable of killing the infecting bacteria, whereas others are 
bacteriostatic, inhibiting the growth or reproduction of the bacterial cells[12]. Some drugs 
are regarded as having a broad spectrum of clinical activity and are used against a wide 
range of gram-negatives and gram-positives, in contrast others have a relatively narrow 
spectrum of clinical activity. Antibacterial drugs also differ in their bacterial targets and 
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mechanisms of action. Important targets for clinical antibacterial drugs include cell wall 
biosynthesis and membrane integrity, folic acid metabolism, protein synthesis, and DNA 
replication and transcription. 
 
Figure 2. Antibiotic classification and mechansim[11] 
 
2.3  GRAM-NEGATIVE BACTERIA 
Gram-negative bacteria are distinct by virtue of their comparably thin peptidoglycan cell 
wall which does not retain the crystal violet stain used in Gram staining[13]. Gram-negative 
bacteria are ubiquitous. The gram-negative bacteria include the model organism 
Escherichia coli, and many pathogenic bacteria, such as Pseudomonas aeruginosa, 
Klebsiella pneumoniae, and Acinetobacter baumanii. They are an important public health 
challenge. Their outer membrane protects them from many antibiotics (including 
penicillin), detergents that would normally damage the peptidoglycans of the (inner) cell 
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membrane, and lysozyme, an antimicrobial enzyme produced by animals that form part of 
the innate immune system. Gram-negative bacteria (GNB) differ from gram-positive 
bacteria with respect to the structure of the cell wall. This results in differences in the 
penetration and retention of chemical agents. Gram-negative bacteria have what is referred 
to as an envelope, consisting of three principal layers: the outer membrane, containing the 
lipopolysaccharide/endotoxin, the peptidoglycan cell wall with peptide chains, partially 
cross-linked, and the cytoplasmic or inner membrane.shock[14, 15]. Several antibiotics 
classes have been designed to target gram-negative bacteria, including aminopenicillins, 
ureidopenicillins, cephalosporins, ßeta-lactam-betalactamase inhibitor combinations (e.g., 
piperacillin-tazobactam). 
2.4  MULTIDRUG RESISTANCE IN GRAM-NEGATIVE BACTERIA  
The internationally accepted definition for multidrug resistance is the non-susceptibility of a 
bacteria isolate to at least one agent in three or more antimicrobial classes. Other 
categorizations are extensively drug-resistant (XDR) is defined as non-susceptibility to at 
least one agent in all, but two or fewer antimicrobial categories, and pan drug-resistant as 
non-susceptibility to all agents in all available antimicrobial categories [16]. Antibiotic 
resistance can be naturally occurring to specific bacteria, generally due to their structural 
and metabolic composition. Gram-negative Organisms are naturally resistant to 
Vancomycin., for example, is due primarily to the inability of the compound to permeate 
the cell wall of the organism. ßeta-lactamase production by Klebsiella species renders it 
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resistant to ampicillin. Pseudomonas aeruginosa is naturally insensitive, e.g., to 
sulphonamides, tetracycline, chloramphenicol, and trimethoprim[15]. 
Some bacteria develop resistance over time due to mutations in bacterial DNA, thereby 
rendering antibiotics ineffective, conveying a survival advantage to the mutated bacterial 
strain. This means that bacteria without these advantages die or cannot reproduce in the 
presence of antibiotic agents, while resistant bacteria can proliferate with less competition. 
Mutations in chromosomal genes can induce an increase in the expression of intrinsic 
resistance mechanisms (antibiotic-inactivating enzymes or efflux pumps)[17]. Some 
resistance is conferred on bacteria from other bacteria either of the same species or form 
other species or genus. The Mechanism used for the transfer of resistance genes from one 
bacterium to the other is conjugation, transduction, and transformation. Vectors carrying 
one or more resistance genes may be plasmids (resistance plasmid 1 is a typical example in 
GNB), transposons (e.g. Tn5053), or integrons e.g. (Verona integron-encoded metallo-ßeta-
lactamase producing GNB)[15]. As for GNB, particulary for Enterobacteriaceae, there is 
evidence suggesting that resistance genes and associated insertion elements carried on 
plasmids are often found concentrated in large multi-resistance regions (MRR) [18]. For 
instance, ESBL- and carbapenemase-encoding plasmids may carry resistance determinants 
for other antimicrobial groups, including aminoglycosides and fluoroquinolones[17]. 
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Recent studies have established the possibility of plasmid-mediated horizontal transmission 
of resistant genes e.g., ESBL-genes, from animals to humans through the food chain[19, 
20].  
2.4.1 Acinetobacter baumannii 
Acinetobacter baumannii is an aerobic gram-negative bacterium and the major caused of 
healthcare-associated infections worldwide. It is one of the ESKAPE pathogen that 
threatens the fight against infectious disease control due to the high non-susceptibilty to 
may class of anitibiotics [21].A. baumannii rapidly develops resistance to antimicrobials by 
different mechanisms such as the inactivation of β-lactams by β-lactamases which is 
considered as a major MDR mechanism in A. baumannii. 
Another resistance way is multidrug efflux pumps against many different classes of 
antibiotics classes, including tigecycline or imipenem resistance in A. baumannii. The 
resistance of A. baumannii to aminoglycoside is mediated by three classes of enzymes, 
including acetyltransferases, adenyltransferases, and phosphotransferases[22]. These 
enzymes chemically modify aminoglycosides. The coding genes can be transferred through 
plasmids, transposons, and integrons. Another is the alterating of target sites, such as 
penicillin-binding proteins (PBPs), mutations of DNA gyrase, and others, alter the target 
sites for antibiotics. Overexpression of certain PBPs results in imipenem resistance and 
mutation in DNA gyrase as in the cases of quinolone and tetracycline resistance in A. 
baumannii[23]. 
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2.4.2 Enterobacteriaceae 
Enterobacteriaceae is a large family of organisms such as Escherichia coli, Klebsiella sp., 
and Enterobacter spp. is the primay cause of urinary tract infections (UTIs), blood-stream 
infections, hospital, and healthcare-associated pneumonia. Resistance is mainly related to 
the production of ESBLs, but other mechanisms of resistance are also emerging, leading to 
multidrug-resistance (MDR) [24]. There is resistance of Enterobacteriaceae to third 
generation Cephalosporin-Resistant with the employment of mechanism like mutation of 
genes encoding TEM-1, TEM-2, or SHV-1 gives rise to new β-lactamases that can 
hydrolyze them. Enterobacteriaceae may also expresses other types of ESBLs like CTX-M 
that hydrolyzes cefotaxime more efficiently than ceftazidime and carbapenem hydrolyzing 
oxacillinases (OXA), which are mainly found in P. aeruginosa and rarely in 
Enterobacteriaceae. In addition to ESBLs, AmpC β-lactamases are also able to hydrolyze 
third-generation cephalosporins and are resistant to inhibition by clavulanate and other β-
lactamase inhibitors [24] 
2.4.3 Pseudomonas aeruginosa 
Pseudomonas aeruginosa is a gram-negative aerobic bacterium commensally found in the 
intestinal flora. However, it is is also classified as an ESKAPE organism responsible for 
ICU-acquired infections in critically ill patients globally. Several mechanisms account for 
its antibiotic resistance: innate resistance of P. aeruginosa such as over-expression of efflux 
pumps and decreasing outer membrane permeability and acquired resistance mechanisms 
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like the acquisition of resistance genes or mutation in genes encode for porins and other 
proteins these all can make this microorganism challenging to treat. 
2.5  EPIDEMIOLOGY OF MULTI-DRUG RESISTANT GRAM-NEGATIVE 
BACTERIA  
The morbidity and mortality associated with gram-negative multidrug-resistant  bacteria 
(GNB-MDR) are particularly concerning as new antimicrobial agents, with susceptibility 
ability to inhibit proliferation of these organisms have not been discovered and developed 
as fast as might have been required[25].Health-care-acquired infections continuously 
remain a global public health concern, particularly for critically ill inpatients and for 
patients requiring placement of invasive devices or surgical procedures. According to the 
WHO, carbapenem resistance in Klebsiella pneumoniae a last-resort treatment, has spread 
to all regions of the world. Klebsiella pneumoniae is a major cause of hospital-acquired 
infections such as pneumonia, bloodstream infections, and infections in newborns and 
intensive-care unit patients. In some countries, carbapenem antibiotics do not work in more 
than half of people treated for Klebsiella pneumoniae infections. 
Resistance in E. coli to one of the most widely used medicines for treating of urinary tract 
infections (fluoroquinolone antibiotics) is pervasive. There are countries in many parts of 
the world where this treatment is now ineffective in more than half of patients. serious 
therapeutic dilemmas because of their complex resistance profiles[25, 26]  
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Studies conducted in other countries of the WHO African Region have shown a significant 
increase in the prevalence of MDR on the continent.  A 12-month AMR survey conducted 
from October 2011 to September 2012 at a tertiary facility in Cape Town, South Africa, 
found that for healthcare-associated Enterobacteriaceae bloodstream isolates, susceptibility 
rates were 58.5%, ceftriaxone, 64.6%, gentamicin, and 70%, ciprofloxacin. The study also 
found that for healthcare-associated Pseudomonas and Acinetobacter strains; they showed 
less than 80% susceptibility to all antibiotics tested except colistin[21]. This finding was 
consistent with other studies done in Rwanda and Kwazulu-Natal. It was concluded that 
there is an urgent need for infection control intervention in these countries due to high 
prevalence rate of MDR among gram-negative bacteria. The study in Rwanda, which  
retrospectively reviewed AST results over a five year period found Klebsiella spp. be most 
susceptible to colistin (99.8%), imipenem (89.4%), and norfloxacin (69.8%); and least 
susceptible to piperacillin (18.2%), amoxicillin–clavulanate (24.6%), ceftriaxone (24.8%), 
and cotrimoxazole (28.4%)[27]. The same study also reported significant resistance among 
commonly used antibiotics in most gram-negative pathogens. Studies on multidrug 
resistance conducted in Ghana in a tertiary healthcare facility by Agyepong et al. also 
reported findings similar to what has been observed across the continent. The study found 
that isolates showed high resistance to ampicillin (94.4%), trimethoprim/sulfamethoxazole 
(84.5%), cefuroxime (79.0%) and cefotaxime (71.3%) but low resistance to ertapenem 
(1.5%), meropenem (3%) and amikacin (11%). It also determined the average multi-drug 
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resistance was 89.5% and ranged from 53.8% in Enterobacter spp. to 100.0% in 
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3 MATERIALS AND METHODS 
3.1 STUDY DESIGN 
This retrospective study analyzed gram-negative bacteria isolates and sensitivity test results 
of patients who visited the Tamale Teaching Hospital laboratory in Ghana, West Africa, 
from 2017 to 2019. 
3.2 STUDY SITE 
This study was conducted with data from the Tamale Teaching Hospital Laboratory. The 
Tamale Teaching Hospital is the only tertiary health care and referral facility responsible 
for serving patients from Northern, Upper West, Upper East, Northern Volta, and parts of 
the Bono Ahafo Regions of Ghana.  
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Figure 3. Map of Depicting Northern Ghana and patient referral coverage area of 
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3.3 SAMPLE SIZE 
The sample size included Antimicrobial Susceptibility Testing results of gram-negative 
bacteria isolates conducted in the Tamale Teaching Hospital Laboratory from January 2017 
to December 2019.  The list of WHO priority gram-negative bacteria include Acinetobacter 
baumanii, Pseudomonas aeruginosa, Enterobacteriaceae [Klebsiella pneumoniae, 
Escherichia coli, Enterobacter spp., Serratia spp., Proteus spp., and Providencia spp., 
Morganella spp.] which classified as critical priority according to WHO priority list[30]. 
High Priority gram-negative organisms include Helicobacter pylori, Campylobacter, 
Salmonella spp. and Neisseria gonorrhoeae. The final category of priority pathogens 
classified as medium priority has two gram-negative bacteria; Haemophilus influenzae and 
Shigella spp[30]. Information on diagnosis, sex, age, and ward type was obtained from 
patients’ records from the laboratory sample registration system. 
3.4 ANTIMICROBIAL SUSCEPTIBILITY TESTING (AST) AND 
DETERMINATION OF MULTIDRUG-RESISTANCE  
The AST was done on each isolated gram-negative bacteria using the disk diffusion 
method.[31] Minimum inhibitory concentrations (MICs) of a panel of antibiotics were 
determined and interpreted according to the guidelines of the Clinical and Laboratory 
Standards Institute (CLSI) [32]. 
Multidrug resistance in this study was defined as isolates that are resistant to at least one 
agent in three or more antibiotic classes according to Magiorakos et al. [16] 
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3.5 STATISTICAL ANALYSIS 
The antimicrobial susceptibility will be expressed as a percentage of the total same species 
isolates that were resistant to a particular antimicrobial. This will be calculated on an annual 
basis (calendar year- 2017,2018,2019), and trends will be assessed from year to year over 
the entire study period for each bacterial organism. Average annual susceptibility over the 
entire study period will be calculated to provide insight on overall antimicrobial 
susceptibility patterns.  
3.6 ETHICAL CONSIDERATION 
Ethical review was obtained from the Institutional Review Board (IRB) of Yonsei 
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4 RESULTS 
4.1  AGE DISTRIBUTION AMONG GENDER AND SAMPLES CULTURED 
The gender distribution of clinical samples cultured with the isolation gram-negative 
bacteria is almost equal proportions between males and females. Sample cultured from 
females amounted to 1406, constituting about 51% of the total cultures that isolated gram-
negative bacteria, as shown in Table 4.1. A total of 1297 gram-negative bacteria were 
isolated from urine samples representing 46.8% of all the isolates followed by isolates, from 
sputum samples and wound swabs, as shown in Table 4.1. Most bloodstream gram-negative 
infections were realized in children below the age of 10, with a high of 52 gram-negative 
isolates making up 67% of all gram-negative bloodstream infections. 
The Elderly above the age of 60 were found to be susceptible to respiratory infections 
accounting for the highest gram-negative isolates from sputum. Gram-negative isolates 
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Female 162 88 413 301 161 82 75 106 1406 
Male 159 79 123 159 132 132 168 411 1363 
Total 321 167 536 460 293 214 243 517 2769 
Clinical Samples 
Aspirate
s & Fluids* 6 7 12 17 9 5 6 4 66 
Blood 52 4 4 5 5 4 3 2 79 
Semen  1 1 11 3 1 1  18 
Sputum 20 32 56 61 101 76 86 148 580 
Stool 1  3 6 2    12 
Swabs* 12 21 152 99 28 5 5 2 324 
Tissue  2 2  1     5 
Urine  195 56 213 183 84 99 113 354 1297 
Wound  30 41 84 76 63 30 37 37 398 
TOTAL 321 167 536 460 293 214 243 517 2769 
*Abscess, Ascetic Fluid, Aspirates, Pleural effusions, CSF ** Vaginal swab, Endocervical swab, Anal swab, 
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4.2 DISTRIBUTION OF GRAM-NEGATIVE BACTERIA FROM CLINICAL 
SAMPLES CULTURED FROM 2017 -2019 
Escherichia coli (23.8%) is the highest isolated gram-negative bacteria in all samples with 
predominance from urine samples making up 33.2%. most gram-negative bacteria were 
isolated from urine samples. As shown in Table 4.2 bloodstream infections were dominated 
by Enterobacter sp. (22.0%) followed by Klebsiella sp. with (20.7%). Respiratory isolates 
were dominated by Klebsiella sp. (21%). 
Table 4.2 Distribution of GNB from clinical samples cultured from 2017 -2019 
 No. of isolates in clinical sample (%) 
Spieces Blood GIT Respiratory Urine Wound Total 
A. baumannii 3(3.7) 1(1.7) 3(0.5) 6(0.4)  13(0.5) 




spp 18(22.0) 8(13.3) 94(15.3) 159(9.9) 39(9.6) 
318(11
.5) 
E. coli 11(13.4) 15(25.0) 43(7.0) 534(33.2) 57(14.1) 
660(23
.8) 
K. pnuemoniae 17(20.7) 15(25.0) 129(21.0) 388(24.1) 77(19.0) 
626(22
.6) 
M. morganii 1(1.2) 1(1.7) 9(1.5) 45(2.8) 5(1.2) 61(2.2) 
Proteus spp 1(1.2) 3(5.0) 20(3.3) 84(5.2) 66(16.3) 
174(6.
3) 
P. rettgeri    12(0.8) 5(1.2) 17(0.6) 
P. aeruginosa 16(19.5) 9(15.0) 87(14.2) 152(9.5) 111(27.4) 
375(13
.5) 
Salmonella spp 2(2.4) 2(3.3)  1(0.1)  5(0.2) 
Serratia spp 1(1.2)  1(0.2) 7(0.4) 3(0.7) 12(0.4) 
Shigella spp 3(3.7) 4(6.7)  4(0.3)  11(0.4) 
Total  82(100) 60(100) 615(100) 1607(100) 405(100) 
2769(1
00) 
Abbreviations: Gram-negative bacteria (GNB), Gastrointestinal Tract (GIT), Percentage of species isolated in 
particular clinical sample (%)  
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4.3 MDR AMONG ISOLATED GRAM-NEGATIVE BACTERIA 
All gram-negative bacteria isolated from 2017-2019 showed significant multi-drug 
resistance between 60% and 95.5%. Moraxella catarrhalis showed the highest multi-drug 
resistance (95.5%) of all bacteria with 100 and above isolates. Priority gram-negative 
bacteria were all determined to have resistance to above 60% of drugs tested. Acinetobacter 
baumanii (83.3%), Citrobacter sp. (91.4%), Enterobacter spp. (84.2%), Escherichia coli 
(84.2%), and Klebsiella pneumoniae (88.8%) were all determined to have multidrug 
resistance above 80%. Pseudomanas aeruginosa isolated from 2017 to 2019 was 
determined to have an average multidrug resistance of 65.8% as shown in Table 4.3. 
The data showed a progressive increment in the levels of resistance among gram-negative 
bacteria from 2017 to 2019. Citrobacter spp showed an increase in multidrug resistance 
from 89.1% in 2017 to 98% in 2019. Klebsiella pneumoniae similarly showed increased 
levels of multidrug resistance year on year; 2017(84%), 2018(89.5%) and 95.1% in 2019. 
Pseudomanas aeruginosa which showed relatively low levels of multidrug resistance 
(65.8%), was still determined to demonstrate increased resistance from 2017 (59.5%) to 
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Table 4.3 MDR among isolated Gram-negative Bacteria (2017-2019) 
 2017 2018 2019 
Total (2017-
2019) 
Speices n MDR (%) n MDR (%) n MDR (%) n 
MDR 
(%) 
A. baumanii 5 4(80.0) 3 3(100) 4 3(75.0) 12 
10(83.
3) 
Citrobacter spp 124 108(89.1) 140 130(92.9) 51 50(98.0) 315 
288(91
.4) 
Enterobacter spp 111 87(78.4) 128 112(87.5) 84 73(86.9) 323 
272(84
.2) 
Escherichia coli 230 193(83.9) 285 261(91.6) 147 133(90.5) 662 
587(88
.7) 
K. pneumoniae 181 152(84.0) 351 314(89.5) 101 96(95.1) 633 
562(88
.8) 
M. morganii 11 9(81.8) 41 38(92.7) 8 8(100) 60 
55(91.
7) 
Proteus spp 58 47(81.0) 89 80((89.9) 33 31(93.9) 180 
158(87
.8) 
P. rettgeri 4 4(100) 9 9(100) 4 3(75.0) 17 
16(94.
1) 
P. aeruginosa 153 91(59.5) 161 106(65.8) 75 59(78.7) 389 
256(65
.8) 
Salmonella spp 2 1((50.0) 3 2(66.7)   5 
3(60.0
) 
Serratia spp 2 1((50.0) 10 10(100)   12 
11(91.
7) 
Shigella spp 4 4(100) 6 5(83.3) 1 1(100) 11 
10(90.
9) 
number of species isolated in year (n), number of Multidrug resistant organisms isolated (MDR), percentage of 
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4.4 RESISTANCE PROFILE OF GRAM-NEGATIVE BACTERIA (2017-2019) 
Resistance to Ampicillin was highest among all Enterobacteriales tested. Enterobacter spp, 
Escherichia coli and Klebsiella pneumoniae were demonstrated to have a resistance of 
above 97% to ampicillin as shown in Table 4.4. Gram-negative bacteria showed the highest 
susceptibility to antibiotics in the aminoglycoside class, with amikacin the most effective. 
Enterobacter spp resistance to Amikacin was as low as 16.2%, Escherichia coli (11.8%) 
and Klebsiella pneumoniae were determined to be 17.7%, as shown in Table 4.4. 
Acinetobacter baumannii demonstrated the highest resistance to amikacin with a resistance 
of 42.8%.  All major gram-negative bacteria were shown to have significant resistance 
against Tetracyclin, trimethoprim-sulfamethoxazole, and Nalidixic Acid, as shown in Table 
4.4. 
There is varied suceptibilty to fluoroquinolones among different gram-negative bacteria. 
Acinetobacter baumanii was determined to have a resistance of 28.6 % and 30.0% 
levofloxacin and ciprofloxacin, respectively. Pseudomonas aeruginosa was shown to be 
more resistant to levofloxacin (53.7%) as compare to ciprofloxacin with a resistance rate of 
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Table 4.4 Resistance Profile of major gram-negative pathogens (2017-2019) 
 
 














AMK 7(42.8) 198(16.2) 383(11.8) 425(17.7) 242(19.4) 
AMP NT 156(98.7) 241(97.9) 272(97.4) NT 
CFP NT 69(84.1) 186(77.4) 188(88.3) NT 
CTX 8(87.5) 196(76.0) 448(69.2) 369(77) NT 
CRO 9(55.5) 242(73.6) 477(68.6) 416(76.7) NT 
CXM NT 120(89.2) 190(77.4) 206(84.4) NT 
CHL NT 76(56.6) 136(50.) 181(67.4) NT 
SXT 5(40.0) 166(68.7) 275(89.5) 273(79.5) 
 
NT 
CIP 10(30.0) 287(42.5) 591(65.3) 555(54.1) 354(39.6) 
GEN 12(33.3) 302(45) 644(31.7) 579(46.1) 355(42.5) 
LVX 7(28.6) 185(45.4) 410(70.7) 415(55.5) 203(53.7) 
NAL NT 91(82.4) 262(90.1) 222(78.8) NT 
NIT NT 117(88.0) 325(53.2) 269(90.7) NT 
TZP 1(100) 95(83.2) 263(72.2) 204(77.5) 88(77.3) 
TET 8(87.5) 144(95.1) 309(96.8) 354(96.1) NT 
Abbreviations: Not tested (NT), amikacin (AMK), ampicillin (AMP), cefoperazone (CFP), cefotaxime (CTX), 
ceftriazone (CRO), chloramphenicol (CHL), trimethoprim-sulfamethoxazole (SXT), ciprofloxacin (CIP), 
gentamicin (GEN), levofloxacin (LVX), nalidixic acid (NAL), nitrofurantoin (NIT), Piperacillin-tazobactam 
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5 DISCUSSION 
Epidemiological and laboratory surveillance of bacterial infection and multidrug resistance 
to antibiotics are essential for informing antimicrobial stewardship and implementation of 
infection prevention and control measures. This becomes more imperative in low-and-
middle-income countries where the studies have shown the lack of laboratory diagnostic 
capacity, poor implementation of infection control measures, and a deficit in the awareness 
of infections caused by multidrug-resistant bacteria, which have resulted in high mortality 
and morbidity.[33, 34]. 
This study’s main purpose was to determine the rate of multidrug resistance in gram-
negative bacteria in a tertiary healthcare facility. The study observed a high prevalence of 
infections among children below the age of 10 and the elderly above 60. This distribution of 
bacterial is similar to the finding by Agypepong et al.[28]. The elderly and infants are 
usually more disposed to infections due to their incompetent immune status. The advancing 
age is commonly associated with risk factors including reduced immunity, co-morbidity 
with other diseases such as non-communicable diseases like diabetes, cardiovascular 
diseases, and renal disorders while in infants, lack of fully developed immunity, 
malnutrition and inadequate hygiene put them at greater risk of infections.[35-37]. This 
study observed a urinary tract infection (58.0%) to be the most common form of gram-
negative bacteria infection with a high disease burden on Northern Ghana’s population. 
Similar studies in Ghana and Sub saharan African region depicts similar findings. The 
finding of this study is comparable to other studies that determined similar trends in gram-
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negative infection patterns.[38-40]. Studies in Korea also came to the finding implicating 
Enterobacterales; Escherichia coli, and Klebsiella pneumoniae as the major causative 
organism in urinary tract infections[41]. Other studies have associated the high levels of 
urinary tract infections, especially among females in middle age groups to be associated 
with sexual activity and poor personal hygiene[38]. Escherichia coli (23.8%) and Klebsiella 
pneumoniae (22.6%) were observed to be the most common gram-negative bacteria 
pathogen responsible for infections among patients at the health facility. Several similar 
studies conducted in other healthcare facilities in Ghana observed the same trend, with 
Escherichia coli and Klebsiella pneumoniae been the most predominant of the pathogens 
responsible for infections [28, 42]. Klebsiella pneumoniae and Pseudomonas aureginosa 
were determined to be the highest causes of blood stream infections accounting for 20.7% 
and 19.5% respectively of all bloodstream infections observed. The results agrees with a 
similar study done in Rwanda and Gabon  which observed the major cause of bloodstream 
infections to be Klebsiella pnuemoniae [43, 44]. However, a multicenter hospital 
survellaince study conducted in Korea observed Escherichia coli (47.1%) was the major 
cause of bacteremia in community-acquired bloodstream infection followed by Klebsiella 
pneumoniae (12.6%) [45]. The major causative organisms for wound infection in this study 
was observed to be Pseudomonas aureginosa (27.4%), Klebsiella pneumoniae (19.0%) and 
Proteus spp (16.3%).This results is comparable to results found in a study of wound 
infection in Ghana where it was observed that the major gram-negative bacteria responsible 
for infection in burns patients was Escherichia coli, Klebsiella pneumoniae and 
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Pseudomonas aeruginosa [46]. The factors associated with wound infections in hospital 
setting has been suggested to be poorly implemented infection prevention and control, 
personal hygiene, and a lack of proper wound care. This study observed increase in the 
trend of the rate of resistance to all antibiotic groups among major gram-negative bacteria 
isolated in northern Ghana from 2017 to 2019.  
This study determined that the resistance of gram-negative bacteria to commonly prescribed 
antimicrobial is extensive. This study indicated multidrug resistance rates of between 60.0% 
in Salmonella typhi to and 95.5% in Moraxella catarrhalis. Major clinically significant 
gram-negative bacteria like Pseudomonas aureginosa (65.8%), Escherichia coli (88.7%), 
Acinetobacter baumannii (83.3%), and Klebsiella pneumoniae (88.8%) as reported in Table 
4.3. These results should be interpreted with the backdrop that the study site is a tertiary 
health care referral facility. That will suggest that majority of the samples received are from 
severly ill patients who may have received empirical antimicrobial therapy at different 
levels of the healthcare system. The other factors associated with the observed high levels 
of multidrug resistance is accounted for by widespread unnecessary and overuse of 
antimicrobials due to lack of appropriate regulations in the sales and administration of 
antimicrobials, counterfeit and low-quality antimicrobials resulting in a sub-inhibitory 
concentration of in vivo and the high rate of self-medication as stipulated in a 2017 study of 
the use of antimicrobials in low-and-middle-income countries[47]. This result is 
comparable to studies done in Ghana in a similar setting with the same definition for 
mutltidrug resistance [38, 42]. Agyepong et al. showed MDR rates in a tertiary healthcare 
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facility in Ghana to be 89.9% in Escherichia coli , 94.7% in Klebsiella pnuemoniae ,100% 
in Acinetobacter baumanii and 100 % in Pseudomonas aeruginosa [28] . However, the 
MDR rates in this study (65.8%) was found to be lower than what was found in the study 
by Agyepong et al. (100%).  
The resistance profile of major gram-negative bacteria isolated displayed high-level 
multidrug resistance with high resistance to ampicillin; Enterobacter spp (98.7%), 
Escherichia coli (97.9%), and Klebsiella pnuemoniae (97.4%). The degree of resistance 
showed in the study was consistent with studies done in Ghana[28, 38, 42]  and also agreed 
with other studies conducted in the sub-Sahara African countries such as Ethiopia, 
Zimbabwe and Rwanda [27, 48, 49]. Resistance to fluoroquinolones among major gram-
negative was reported in this study to be range between 28.6% Acinetobacter baumannii 
resistance to levofloxacin to 65.3% Escherichia coli resistance to Ciprofloxacin. As shown 
in Table 4.4. Comparatively, major gram-negative pathogens exhibited the least resistance 
to aminoglycosides. Resistance to amikacin among major pathogens isolated were observed 
to be 42.8% in Acinetobacter baumannii and 19.4% in Pseudomanas aeruginosa. 
Enterobacteriacaea resistance to amikacin ranged from 11.8% in Escherichia coli to 17.7% 
in Klebsiella pnuemoniae as shown in Table 4. These findings were consistent with studies 
conducted in Ghana [28]  and also comparable to studies in other parts of Africa[50, 51]. 
The observation of a increased resistance trend in the African sub-region is indicative of 
high antibiotic selection pressure mainly due to availability and easy accessibility of 
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counterfeit antimicrobials with suboptimal inhibitory concentrations, high levels of self-
medication  and the lack of antimicrobial stewardship programs in both communities and 
health care setting [47]. This study limitations includes the use of retrospective data which 
may have varying consistency. The study site used disk diffusion method which is 
qualitative in its interpretation of minimum inhibitory concentration using CLSI guidelines. 
The samples were cultured, and an antimicrobial susceptibility test performed in a referral 
tertiary healthcare facility, and as such the results should be interpreted in that context. 
Based on the observed high level of, and increasing trend of resistance among gram-
negative pathogens, there is an urgent need for the institution of Antimicrobial Stewardship 
Programs in hospitals and the community. The is also a need for regulation and education 
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6 CONCLUSIONS  
The study has shown high levels of multidrug-resistant gram-negative bacteria commonly 
isolated as the causative organisms in a range of infections. The predominant gram-negative 
bacteria implicated in infections in the Tamale Teaching Hospital were Escherichia coli, 
Klebsiella pneumoniae and Pseudomonas aeruginosa. There is high resistance to 
penicillins, cepholosporins and fluoroquinolones among major gram-negative pathogens. 
Aminoglycosides exhibited the least levels of resistance to isolated gram-negative bacteria 
in the Tamale Teaching Hospital.  
The conduction of nationwide surveilance of multidrug resistance is a resource intensitive 
endeavour and have proven to be difficult to undertake in low- and middle-income 
countries like Ghana. This study will be helpful in informing policy direction on infection 




   32 
REFERENCES 
1. Organization, W.H., Antimicrobial resistance: global report on surveillance. 2014: 
World Health Organization. 
2. O’neill, J.J.R.A.R., Antimicrobial resistance: tackling a crisis for the health and 
wealth of nations. 2014. 20:  1-16. 
3. Singh, N., V.J.C.M. Manchanda, and Infection, Control of multidrug-resistant 
gram-negative bacteria in low-and middle-income countries—high impact 
interventions without much resources. 2017. 23(4):  216-218. 
4. Ayukekbong, J.A., et al., The threat of antimicrobial resistance in developing 
countries: causes and control strategies. 2017. 6(1):  47. 
5. Huttner, A., et al., Antimicrobial resistance: a global view from the 2013 World 
Healthcare-Associated Infections Forum. 2013. 2(1):  31. 
6. Newman, M.J., et al., Resistance to antimicrobial drugs in Ghana. 2011. 4:  215. 
7. Opintan, J.A., M.J.J.A.R. Newman, and I. Control, Prevalence of antimicrobial 
resistant pathogens from blood cultures: results from a laboratory based 
nationwide surveillance in Ghana. 2017. 6(1):  64. 
8. Karlowsky, J.A., et al., Resistance among Gram-negative ESKAPE pathogens 
isolated from hospitalized patients with intra-abdominal and urinary tract 
infections in Latin American countries: SMART 2013-2015. Brazilian Journal of 
Infectious Diseases, 2017. 21(3):  343-348. 
   33 
9. Karlowsky, J.A., et al., Antimicrobial susceptibility of Gram-negative ESKAPE 
pathogens isolated from hospitalized patients with intra-abdominal and urinary 
tract infections in Asia–Pacific countries: SMART 2013–2015. Journal of medical 
microbiology, 2017. 66(1):  61-69. 
10. Zhen, X., et al., Economic burden of antibiotic resistance in ESKAPE organisms: a 
systematic review. Antimicrobial Resistance & Infection Control, 2019. 8(1):  137. 
11. Pietsch, F., Evolution of antibiotic resistance. 2015, Acta Universitatis Upsaliensis. 
12. Aminov, R.I., The role of antibiotics and antibiotic resistance in nature. 
Environmental microbiology, 2009. 11(12):  2970-2988. 
13. Salton, M.R., K.-S. Kim, and S. Baron, Medical microbiology. S. Baron (ed.), 
1996. 
14. Pelletier Jr, L.L., Microbiology of the circulatory system, in Medical Microbiology. 
4th edition. 1996, University of Texas Medical Branch at Galveston. 
15. Exner, M., et al., Antibiotic resistance: What is so special about multidrug-resistant 
Gram-negative bacteria? GMS hygiene and infection control, 2017. 12. 
16. Magiorakos, A.-P., et al., Multidrug-resistant, extensively drug-resistant and 
pandrug-resistant bacteria: an international expert proposal for interim standard 
definitions for acquired resistance. Clinical microbiology and infection, 2012. 
18(3):  268-281. 
17. Ruppé, É., P.-L. Woerther, and F. Barbier, Mechanisms of antimicrobial resistance 
in Gram-negative bacilli. Annals of intensive care, 2015. 5(1):  21. 
   34 
18. Partridge, S.R., Analysis of antibiotic resistance regions in Gram-negative 
bacteria. FEMS microbiology reviews, 2011. 35(5):  820-855. 
19. Huang, C., et al., Clinical features of patients infected with 2019 novel coronavirus 
in Wuhan, China. The lancet, 2020. 395(10223):  497-506. 
20. Leverstein‐van Hall, M., et al., Dutch patients, retail chicken meat and poultry 
share the same ESBL genes, plasmids and strains. Clinical Microbiology and 
Infection, 2011. 17(6):  873-880. 
21. McKay, R. and C. Bamford, Community-versus healthcare-acquired bloodstream 
infections at groote schuur hospital, cape town, South Africa. South African 
Medical Journal, 2015. 105(5):  363-369. 
22. Breijyeh, Z., B. Jubeh, and R. Karaman, Resistance of Gram-negative bacteria to 
current antibacterial agents and approaches to resolve it. Molecules, 2020. 25(6):  
1340. 
23. Gonzalez-Villoria, A.M. and V. Valverde-Garduno, Antibiotic-resistant 
Acinetobacter baumannii increasing success remains a challenge as a nosocomial 
pathogen. Journal of pathogens, 2016. 2016. 
24. Paterson, D.L., Resistance in gram-negative bacteria: Enterobacteriaceae. 
American journal of infection control, 2006. 34(5):  S20-S28. 
25. Boucher, H.W., et al., Bad bugs, no drugs: no ESKAPE! An update from the 
Infectious Diseases Society of America. Clinical infectious diseases, 2009. 48(1):  
1-12. 
   35 
26. Rice, L.B., Federal funding for the study of antimicrobial resistance in nosocomial 
pathogens: no ESKAPE. 2008, The University of Chicago Press. 
27. Carroll, M., et al., Five-year antimicrobial susceptibility trends among bacterial 
isolates from a tertiary health-care facility in Kigali, Rwanda. The American 
journal of tropical medicine and hygiene, 2016. 95(6):  1277-1283. 
28. Agyepong, N., et al., Multidrug-resistant gram-negative bacterial infections in a 
teaching hospital in Ghana. Antimicrobial Resistance & Infection Control, 2018. 
7(1):  37. 
29. Antwi, E.K., et al., Developing a community-based resilience assessment model 
with reference to Northern Ghana. 2014. 
30. Shrivastava, S.R., P.S. Shrivastava, and J. Ramasamy, World health organization 
releases global priority list of antibiotic-resistant bacteria to guide research, 
discovery, and development of new antibiotics. Journal of Medical Society, 2018. 
32(1):  76. 
31. Bayer, A., et al., Antibiotic susceptibility testing by a standardized single disc 
method. Am J clin pathol, 1966. 45(4):  493-496. 
32. CLSI, C., M100-S25: Performance Standards for Antimicrobial Susceptibility 
Testing. Twenty-Fifth Informational Supplement, 2012. 
33. Huttner, A., et al., Antimicrobial resistance: a global view from the 2013 World 
Healthcare-Associated Infections Forum. Antimicrobial resistance and infection 
control, 2013. 2(1):  31. 
   36 
34. Samuel, S., et al., Nosocomial infections and the challenges of control in 
developing countries. African journal of clinical and experimental microbiology, 
2010. 11(2). 
35. Hill, R., et al., Is undernutrition prognostic of infection complications in children 
undergoing surgery? A systematic review. Journal of Hospital Infection, 2016. 
93(1):  12-21. 
36. Simonetti, A.F., et al., Management of community-acquired pneumonia in older 
adults. Therapeutic advances in infectious disease, 2014. 2(1):  3-16. 
37. Chang, Y.-J., et al., Predicting hospital-acquired infections by scoring system with 
simple parameters. PloS one, 2011. 6(8):  23137. 
38. Gyasi-Sarpong, C.K., et al., Resistance pattern of uropathogenic bacteria in males 
with lower urinary tract obstruction in Kumasi, Ghana. African Journal of 
Microbiology Research, 2014. 8(36):  3324-3329. 
39. Obirikorang, C., et al., Asymptomatic Bacteriuria among Pregnant Women 
Attending Antenatal Clinic at the Uni-versity Hospital, Kumasi, Ghana. Journal of 
Medical and Biomedical Sciences, 2012. 1(1):  38-44. 
40. Gyansa-Lutterodt, M., et al., Antimicrobial use and susceptibility pattern of 
uropathogens associated with urinary tract infections at the Ghana Police 
Hospital. Global Journal of Pharmacology, 2014. 8(3):  306-315. 
   37 
41. Kang, C.-I., et al., Clinical practice guidelines for the antibiotic treatment of 
community-acquired urinary tract infections. Infection & chemotherapy, 2018. 
50(1):  67-100. 
42. Newman, M.J., et al., Resistance to antimicrobial drugs in Ghana. Infection and 
drug resistance, 2011. 4:  215. 
43. Ntirenganya, C., et al., High prevalence of antimicrobial resistance among 
common bacterial isolates in a tertiary healthcare facility in Rwanda. The 
American journal of tropical medicine and hygiene, 2015. 92(4):  865-870. 
44. Alabi, A.S., et al., Retrospective analysis of antimicrobial resistance and bacterial 
spectrum of infection in Gabon, Central Africa. BMC infectious diseases, 2013. 
13(1):  455. 
45. Son, J.S., et al., Bloodstream infections and clinical significance of healthcare-
associated bacteremia: a multicenter surveillance study in Korean hospitals. 
Journal of Korean medical science, 2010. 25(7):  992-998. 
46. Forson, O., et al., Bacterial infections in burn wound patients at a tertiary teaching 
hospital in Accra, Ghana. Annals of burns and fire disasters, 2017. 30(2):  116. 
47. Ayukekbong, J.A., M. Ntemgwa, and A.N. Atabe, The threat of antimicrobial 
resistance in developing countries: causes and control strategies. Antimicrobial 
Resistance & Infection Control, 2017. 6(1):  47. 
   38 
48. Muluye, D., et al., Bacterial isolates and their antibiotic susceptibility patterns 
among patients with pus and/or wound discharge at Gondar university hospital. 
BMC research notes, 2014. 7(1):  619. 
49. Mbanga, J., S. Dube, and H. Munyanduki, Prevalence and drug resistance in 
bacteria of the urinary tract infections in Bulawayo province, Zimbabwe. East 
African journal of public health, 2010. 7(3). 
50. Ogbolu, D., et al., High levels of multidrug resistance in clinical isolates of Gram-
negative pathogens from Nigeria. International journal of antimicrobial agents, 
2011. 37(1):  62-66. 
51. Kumburu, H., T. Sonda, and B. Mmbaga, Patterns of infections, aetiological agents 
and antimicrobial resistance at a tertiary care hospital in northern Tanzania. TM 
and IH. 2017; 22 (4): 454–64. Center for Global Health and Medicine (NCGM), 
Tokyo, Japan, 4c, Detroit, Michigan, 5AMR Clinical Reference Center, National 
Center for Global Health and Medicine, Tokyo, Japan Session. 57. 
 
 
